Supported by the French government as part of the France2030 initiative, in collaboration with the Secrétariat général pour l’investissement and the PIIEC Med4Cure, this program is primarily aimed at strengthening France’s health and industrial sovereignty, with a clear ambition to establish a European leadership role in the field of biotherapies.
The goal is to bring new cell therapies to patients who need them, while building a robust and competitive industrial sector.
Thank you to all the partners and stakeholders contributing to this collective ambition.
Thank you to The Drug Cell.
Sergio Manzana Pascale Bouillé
Bruno Bonnell
Roland Lescure Sébastien Martin
Frédéric PACOUD Yann Guivarch
Anne FERRER-VILLENEUVE Julie COURPRON
Sandy SEVRAIN (DARRIGAN)
Stephane Buttin Dominique Ravot
Sylvain Ursuegui
Follow The Drug Cell on LinkedIn!
Contact and further information: Frédéric Gazda
In the Same Category
ENVOL Project: Maison MGA at the Heart of the “Organs-on-a-Chip” Revolution
As regulatory and ethical pressures push the industry to move away from animal testing, a major technological breakthrough is emerging in the Auvergne-Rhône-Alpes region. Maison MGA, through its subsidiary MGA MedTech, is partnering with the ENVOL project to bring the...
MGA featured on BFM Lyon: Health innovation in the spotlight
"Lyon has always been a hub for healthcare. At Maison MGA, we are proud to contribute to this field by designing the technologies that will provide tomorrow's healthcare solutions." It was with these words and unwavering conviction that Hervé de Maillard, our...